Altaviva
Medtronic Neuromodulation · Decision date Sep 14, 2026
What did the FDA decide?
The FDA database entry records a 30-day notice for Altaviva (P240011/S016), decided OK30 on 2026-09-14. The supplement type is a 30-day notice with reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the stated change is "the addition of a manufacturing verification step for the WR9220A and P720R1 wireless rechargers." The source identifies the device category as an implantable tibial electrical stimulator for urinary incontinence, product code QPT, specialties gastroenterology and urology, and the applicant as Medtronic Neuromodulation.
The supplement number tied to PMA P240011 establishes that this notice falls under that original approval rather than constituting a new PMA. The statement covers only an added manufacturing verification step for two named recharger models; it does not describe the verification method, acceptance criteria, affected manufacturing sites, or any clinical data. A reported process-change purpose is not independent evidence of safety or clinical effectiveness, and no new indication or clinical outcome is stated here.
FDA approval order statement
the addition of a manufacturing verification step for the WR9220A and P720R1 wireless rechargers
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 14, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240011/S016
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Neuromodulation
- Product code
- QPT
- Decision code
- OK30
- Decision date
- Sep 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, tibial, electrical, implantable, for urinary incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- QPT
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240011 · Original PMA
Medtronic Altaviva System
P240011/S016 received
Application receipt date recorded by FDA.
P240011/S016 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P240011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Medtronic Altaviva SystemP240011 | Medtronic Neuromodulation | PMA approval | Sep 18, 2025 | FDA |
Explore the linked device profile
Other records with product code QPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
eCoin Peripheral NeurostimulatorP200036/S012 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Sep 9, 2026 | FDA |
| BOSTON SCIENTIFIC CORPORATION | PMA approval | Mar 1, 2022 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave. NE, Ms Rce480, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P240011/S016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
